Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

PURPOSE: New immuno-oncology therapies targeting programmed cell death receptor 1 (PD-1) have improved patient outcomes in a broad range of cancers. The objective of this analysis was to evaluate the PK, pharmacodynamics (PDy), and safety of dostarlimab monotherapy in adult patients with previously-...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnaik, Amita, Weiss, Glen J., Rasco, Drew W., Blaydorn, Lisa, Mirabella, Amy, Beeram, Murali, Guo, Wei, Lu, Sharon, Danaee, Hadi, McEachern, Kristen, Im, Ellie, Sachdev, Jasgit C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739161/
https://www.ncbi.nlm.nih.gov/pubmed/34750637
http://dx.doi.org/10.1007/s00280-021-04358-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739161/
https://www.ncbi.nlm.nih.gov/pubmed/34750637
http://dx.doi.org/10.1007/s00280-021-04358-3

Ejemplares similares